sorting nexin family member 21Genealiases: C20orf161 · PP3993 · SNX-L · SNXL · dJ337O18.4
Q-omics provides the consensus-scored SNX21 profile across patient tissues and cancer cell-line models. SNX21 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SNX21 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, SNX21 protein abundance shows 23,204 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UVM, LIHC, and HNSC as cancer lineages where SNX21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX21 survival associations across molecular data types. SNX21 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX21 RNA expression–survival associations across cancer types. High SNX21 expression shows unfavorable associations in UVM, LGG, ACC and THCA, but favorable associations in LUAD and SARC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SNX21 RNA expression.
This table summarizes SNX21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SNX21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX21 shows lower tumor expression in BLCA, UCEC, BRCA and KIRC and higher tumor expression in LIHC and CHOL. The LIHC box plot shows higher SNX21 RNA expression in tumor versus normal tissue (log2 FC = +0.986, t-test p < 0.001).
This table shows molecular features associated with SNX21 in patient tissues and cancer cell lines. In patient samples, SNX21 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, SNX21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
